Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program

Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part
                         of Its Healthy Minds Program

Donation to British schools will help train future leaders in mental health
research, policy and practice

PR Newswire

LONDON, March 4, 2013

LONDON, March 4, 2013 /PRNewswire/ -- Janssen Pharmaceutica, NV, ("Janssen")
announced today a donation to the Centre for Global Mental Health, a program
of the London School of Hygiene & Tropical Medicine and the Institute of
Psychiatry at King's College, London, to support the Centre's new Global
Mental Health Scholarship Fund. Given as part of Janssen's global Healthy
Minds program, the donation will support the training of future leaders in the
field of mental health with nine scholarships, which will be awarded starting
in the 2013-14 academic year.

Open to honors graduates from around the world, the program is a rigorous
one-year Master's of Science (MSc) course of study in global mental health
research, policy and practice. It is designed to prepare graduates for careers
in national mental health policy and planning, in epidemiological and mental
health services research, and as mental health advisors and advocates in
government ministries, international aid agencies and non-governmental
organizations. The scholarships will cover tuition, room and board,
transportation, books, daily expenses and international travel to London.

"Currently, mental health disorders account for nearly 10 percent of the
global burden of disease, yet there is a deficit in the number of
professionals needed to adequately assess and treat these disorders," said
Husseini K. Manji, M.D., Global Therapeutic Area Head for Neuroscience,
Janssen Research & Development, LLC. "There is an enormous need for
professional training to manage the growing global mental health crisis and
integrate locally appropriate strategies for care into national health
programs and policies. That is precisely the reason why Janssen was compelled
to contribute to the Global Mental Health Scholarship Fund."

The MSc in Global Mental Health program is taught jointly through two
world-renowned postgraduate research and teaching institutions – the London
School of Hygiene & Tropical Medicine and the Institute of Psychiatry, King's
College, London.

"Lack of mental health care is one of the most neglected problems worldwide,"
said Professor Peter Piot, Director of the London School of Hygiene & Tropical
Medicine. "Hundreds of millions of people around the world with mental,
neurological or substance-use disorders do not receive even the most basic
care, even though effective and low-cost treatments exist. One of the aims of
the MSc in Global Mental Health is to train mental health leaders to improve
access to care in countries around the world. It is the first degree of its
kind in the world, and it is being led by the true pioneers in global mental
health at the School and at the Institute of Psychiatry."

The MSc candidates in Global Mental Health receive training in epidemiological
and health services research methods to equip them to monitor and evaluate
mental health programs. They also learn to devise locally appropriate and
feasible strategies to reduce burden of mental health disorders at every
level, from national health policy and systems to individual clinical
interventions. For more information about the program, the course directors
can be contacted at MScGMH@lshtm.ac.uk or gmh-msc@kcl.ac.uk.

"This funding highlights another tangible example of Janssen's dedication to
the advancement of the mental healthcare field," said Jane Griffiths, Company
Group Chairman, Janssen, Europe, Middle East and Africa. "We are confident
that people who complete the program will be highly capable of making a
difference in the lives of people suffering from mental illnesses, especially
those who may lack resources to find and navigate appropriate treatment
options and care."

The London School of Hygiene & Tropical Medicine is a leading center for
research and postgraduate education in public and global health, with 4000
students and more than 1,300 staff working in over 100 countries. The School's
mission is to improve health and health equity in the UK and worldwide;
working in partnership to achieve excellence in public and global health
research, education and translation of knowledge into policy and practice.

About Janssen'sHealthy MindsProgram
Janssen's interests in integrated care for brain diseases have a direct
connection to the JanssenHealthy Mindsprogram, launched in 2011 to encourage
collaboration among biotechnology, pharmaceutical and public-sector
organizations to accelerate the discovery of new therapeutic solutions for
neurologic and brain diseases.Healthy Mindsbuilds on Janssen's longstanding
legacy of achievement in advancing neuroscience research. The company's work
in this area dates back to the 1950s, when Dr. Paul Janssen's discovery and
development work led to one of the first breakthrough treatments for
schizophrenia. Janssen takes its name from "Dr. Paul," who is known as one of
the 20th century's most gifted and passionate physicians and pharmaceutical
researchers.

Over the last half century, Janssen has discovered, developed and launched
many innovative treatments for brain and CNS conditions and remains firmly
committed to neuroscience. Janssen supports public and professional education
about mental illness and brain disorders, and funds sponsorships and
philanthropy in the field of neuroscience and mental health.

About Janssen Pharmaceutica, NV
Janssen Pharmaceutica, NV, based in Beerse, Belgium, ("Janssen") and with an
operating unit in the United Kingdom, is part of the worldwide Pharmaceuticals
Group of Johnson & Johnson. Janssen focuses on the discovery, development and
production of new medicines and diagnostics and on the provision of innovative
therapies for the benefit of patients, doctors and other health care
professionals all over the world. Janssen concentrates its efforts on five
therapeutic research areas: neurosciences, oncology, vaccines and infectious
diseases, immunology, and cardiovascular and metabolic disorders. For more
information, please visit http://en.janssenpharmaceutica.be/.

Media Contacts:
Greg Panico                  David Keown
Janssen Global Services, LLC Janssen UK
908-240-2011 – Cell          +44 (0) 1494 567 498 – Office

SOURCE Janssen Pharmaceutica, NV

Website: http://en.janssenpharmaceutica.be